Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)

NEW YORK--(BUSINESS WIRE)-- Entwistle & Cappucci LLP (“Entwistle & Cappucci”) is investigating potential federal securities law violations on behalf of its clients and other former holders of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) common stock.

Cerevel was a publicly traded biopharmaceutical company that was acquired by AbbVie, Inc. in August 2024. On October 16, 2023, Cerevel conducted a secondary public stock offering of approximately 19 million shares for $22.81 per share. Less than two months later, AbbVie announced it was acquiring Cerevel for $45.00 per share. Entwistle & Cappucci is investigating claims related to the purchases of Cerevel stock by certain Company insiders.

If you sold Cerevel (NASDAQ: CERE) securities from October 11, 2023 through December 6, 2023, or have other information concerning these issues, please contact attorneys Robert N. Cappucci or Andrew M. Sher at 212-894-7200, or via e-mail at rcappucci@entwistle-law.com or asher@entwistle-law.com.

About Entwistle & Cappucci

Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients globally in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, including securities, antitrust, corporate transactions, general corporate and commercial, creditor’s rights and bankruptcy, corporate governance and fiduciary duty, government affairs, insurance, investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331404862/en/

Robert N. Cappucci, Esq. (rcappucci@entwistle-law.com)

Andrew M. Sher, Esq. (asher@entwistle-law.com)

Entwistle & Cappucci LLP

www.entwistle-law.com

230 Park Avenue, 3^rd Floor

New York, NY 10169

Telephone: (212) 894-7200

Source: Entwistle & Cappucci LLP

FAQ

What is the price difference between Cerevel's (CERE) secondary offering and AbbVie's acquisition price?

Cerevel's secondary offering was priced at $22.81 per share, while AbbVie's acquisition price was $45.00 per share, representing a 97.3% premium.

When did Cerevel Therapeutics (CERE) conduct its secondary public offering?

Cerevel conducted a secondary public offering of approximately 19 million shares on October 16, 2023.

What is the timeframe of Entwistle & Cappucci's investigation into Cerevel (CERE)?

The investigation covers the period from October 11, 2023, through December 6, 2023.

What specific aspects of Cerevel's (CERE) stock transactions are being investigated?

The investigation focuses on potential federal securities law violations related to stock purchases by Company insiders during the specified period.